Schedule a Free Consultation: (866) 881-0403
Schedule a Free Consultation: (866) 881-0403

What Patients Need to Know About Blood Clot Filter Problems

Bradley/Grombacher, LLP • August 17, 2017

Have you or someone you know experienced migration and other side effects after having a C.R. Bard inferior vena cava filter implanted? If so, you may be entitled to file a legal claim for compensation.


Medical device manufacturer C.R. Bard has been in the spotlight lately regarding the failure associated with their G2 IVC filter series. These filters were created to replace its initial Recovery filter. However, fatal flaws were associated with G2 filters device that left patients suffering the consequences.

Rather than recalling the G2 filter, the device manufacturer kept these on the market until 2010, for a period of five years, and more than 160,000 of these devices were sold. Hundreds of problems and at least 12 deaths have been associated with the G2 series filters.


An inferior vena cava filter is a medical device implanted inside the patient’s largest vein, called the inferior vena cava. The device returns blood from the body to the heart and was designed to capture blood clots along that pathway that could cause pulmonary embolisms. The primary manufacturer of these devices is C.R. Bard.


The FDA has approved IVC filters to treat the following medical conditions:


  • Chronic pulmonary embolisms when use of an anticoagulant failed
  • Emergency treatment after a massive pulmonary embolism
  • Thromboembolic diseases in which anticoagulant therapy failed
  • Pulmonary embolism


What Patients Need to Know About Blood Clot Filter Problems

Their first-generation filter, the Recovery, was introduced in 2003 and the second generation G2 filter was introduced in 2005. The FDA received more than 900 reports between 2005 and 2010 about serious negative side effects associated with IVC filters breaking down including:


  • Filter fracture
  • Device migration
  • Detached device components
  • Filter perforation


Further research on this brand of IVC filters revealed widespread blood clot filter problems. Some physicians now believe the filters were never safe to be implanted in the first place. Approximately 250,000 individuals across the United States each year receive these implants, but many may be unaware of the deadly blood clot filter problems that can result. When the G2 version replaced the initial Recovery filters, similar adverse event reports were filed by patients.


Documents from Bard indicate that the data showed a high rate of blood clot filter problems. The G2 filter, in particular, had more reported problems, migrations, and fractures than any of the similar products on the market.


Although the IVC filters maintain a history of many adverse event reports and concerns shared by physicians, patients now want to know why the company kept the G2 filters on the market for so long when concerns and injuries were indicated much earlier. Blood clot filter problems can cause death if not captured quickly.


If you or someone you know has already been negatively affected by the G2 IVC filter, you may face grave risks. Contacting your physician immediately is strongly recommended if you have not done so already.



If injuries have already occurred, you may be able to file a legal claim for compensation. The lawyers at Bradley/Grombacher have a track record of helping victims who have suffered due to defective medical devices. Contacting them today for a free consultation about your case.


By kileygrombacher October 9, 2024
The Private Attorneys General Act (PAGA) , a pivotal piece of California labor law, has recently undergone significant reforms that have sparked a mixed response among legal professionals. These changes, signed into law by Governor Gavin Newsom in June 2024, aim to address long-standing concerns from both employers and employees regarding the 20-year-old legislation. However, the compromises have left the legal community divided, with opinions varying widely on the potential outcomes of these adjustments.
By Kiley L. Grombacher June 21, 2023
Bradley/Grombacher LLP
Abercrombie Clothing Lawsuit Leads to $25 Million Dollar Settlement
By Bradley/Grombacher, LLP May 16, 2023
An Abercrombie clothing lawsuit has led to a $25 million settlement over allegations that employees were required to purchase the clothing they were selling in the store.
Join Us For The 2022 Class Action Litigation Conference!
By Marcus J. Bradley September 14, 2022
The program will feature an update of Pending Cases in the 9th Circuit with some SCOTUS discussion, and several important technical issues required for bringing and defending class actions.
By Bradley/Grombacher, LLP June 22, 2022
Marcus Bradley is a founder and partner at Bradley/Grombacher, LLP, and focuses much of his practice on complex consumer litigation, class actions, mass torts, product liability, personal injury, and more.
By Bradley/Grombacher, LLP June 21, 2022
Kiley Grombacher is a founder and partner at Bradley/Grombacher, LLP, and focuses much of her practice in complex litigation including consumer and employment class actions, product liability, and pharmaceutical mass torts.
By Bradley/Grombacher, LLP May 12, 2022
The Harris Martin's MDL Conference is focusing on recalled infant formula and Gardasil.
By Bradley/Grombacher, LLP May 12, 2022
The retreat is designed for attorneys and provides 6 credit hours of continuing legal education (CLE). During the event, Attorney Grombacher will be a featured speaker presenting on PAGA: What's Next After Viking River Cruises?
By Bradley/Grombacher, LLP August 23, 2021
At Bradley/Grombacher, LLP, we invite you to attend HarrisMartin’s Webinar Series: Neutrogena Sunscreen Litigation. Learn more:
By Bradley/Grombacher, LLP November 17, 2020
Bradley/Grombacher Law More parents are reporting the downside of school spirit – cheerleading injuries that can be catastrophic and life altering.
More Posts
Share by: